Routine Application of Ostenil® Mini in Patients with Rhizarthrosis

TRB Chemedica AG110 enrolled

Overview

PMCF study to observe the routine application of Ostenil® Mini in the treatment of pain and restricted mobility in degenerative and traumatic changes of the CMC joint.

Study Type

OBSERVATIONAL

Enrollment

110

Conditions

Rhizarthrosis

Interventions

Ostenil® MiniDEVICE

Ostenil® Mini is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 1.0 % sodium hyaluronate from fermentation

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects ≥ 18 years of age and in good general health condition * Signed informed consent * Existing Ostenil® Mini recommendation for the treatment of rhizarthrosis Exclusion Criteria: * Known hypersensitivity to one of the Ostenil® Mini components * Known pregnancy or lactating females * Presence of coagulation disorder * Subjects not capable of contracting and of understanding the nature, risks, significance and implications of the clinical investigation and unable to form a rational intention in the light of these facts * Subjects unable to understand informed consent or having a high probability of non compliance to the study procedures and / or non completion of the study according to investigator's judgement (e.g. illiteracy, insufficient knowledge of local language)

Locations (6)

Orthopädie am Tauentzien

Berlin, State of Berlin, Germany

Praxis für Orthopädie und Unfallchirurgie

Berlin, Germany

MVZ Berlin Freiheit 1

Berlin, Germany

Orthopädie am Kiesteich

Berlin, Germany